HOMOLOGY MEDICINES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX

NEW ORLEANS, Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Homology Medicines, Inc. (NasdaqGS: FIXX) with Q32 Bio Inc. Under the terms of the proposed transaction, Homology shareholders will end up owning approximately 25% of the combined company, subject to possible adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit  https://www.ksfcounsel.com/cases/nasdaqgs-fixx/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC
1100 Poydras St., Suite 960
New Orleans, LA 70163

View original content to download multimedia:https://www.prnewswire.com/news-releases/homology-medicines-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick--foti-llc-investigates-merger-of-homology-medicines-inc---fixx-302046079.html

SOURCE Kahn Swick & Foti, LLC